Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.01
SHPG's Cash to Debt is ranked lower than
99% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. SHPG: 0.01 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.34 Max: No Debt
Current: 0.01
Equity to Asset 0.43
SHPG's Equity to Asset is ranked lower than
75% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SHPG: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.59 Max: 0.85
Current: 0.43
0.25
0.85
Interest Coverage 19.41
SHPG's Interest Coverage is ranked lower than
76% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 19.41 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 2.96  Med: 24.85 Max: 55.13
Current: 19.41
2.96
55.13
F-Score: 5
Z-Score: 2.23
M-Score: -2.56
WACC vs ROIC
13.57%
11.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.65
SHPG's Operating margin (%) is ranked higher than
87% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. SHPG: 22.65 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 21.37 Max: 35.13
Current: 22.65
-56.61
35.13
Net-margin (%) 19.87
SHPG's Net-margin (%) is ranked higher than
88% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. SHPG: 19.87 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.13 Max: 56.55
Current: 19.87
-59.59
56.55
ROE (%) 13.79
SHPG's ROE (%) is ranked higher than
89% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. SHPG: 13.79 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.82 Max: 49.38
Current: 13.79
-90.17
49.38
ROA (%) 7.08
SHPG's ROA (%) is ranked higher than
87% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. SHPG: 7.08 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.55
Current: 7.08
-37.5
31.55
ROC (Joel Greenblatt) (%) 142.82
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SHPG: 142.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 109.10 Max: 345.44
Current: 142.82
-396.76
345.44
Revenue Growth (3Y)(%) 14.00
SHPG's Revenue Growth (3Y)(%) is ranked higher than
68% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SHPG: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 13.00 Max: 28.5
Current: 14
0
28.5
EBITDA Growth (3Y)(%) 21.00
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SHPG: 21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 24.80 Max: 42.4
Current: 21
-2.3
42.4
EPS Growth (3Y)(%) 24.70
SHPG's EPS Growth (3Y)(%) is ranked higher than
80% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. SHPG: 24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.5  Med: 27.15 Max: 81.1
Current: 24.7
-8.5
81.1
» SHPG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SHPG Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 786,159 sh (New)
Ken Fisher 20,161 sh (+36.31%)
Jim Simons 264,812 sh (+34.07%)
Murray Stahl 6,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Leon Cooperman 496,192 sh (-0.80%)
John Paulson 7,095,100 sh (-14.81%)
Pioneer Investments 75,972 sh (-34.69%)
First Eagle Investment 4,830 sh (-98.36%)
» More
Q3 2015

SHPG Guru Trades in Q3 2015

Steven Cohen 100 sh (New)
Ken Fisher 31,064 sh (+54.08%)
Murray Stahl 6,000 sh (unchged)
First Eagle Investment 4,830 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
John Paulson 6,805,200 sh (-4.09%)
Jim Simons 225,712 sh (-14.77%)
Pioneer Investments 12,019 sh (-84.18%)
Leon Cooperman 45,367 sh (-90.86%)
» More
Q4 2015

SHPG Guru Trades in Q4 2015

Andreas Halvorsen 137,198 sh (New)
Paul Singer 53,943 sh (New)
Steven Cohen 115,800 sh (+115700.00%)
Pioneer Investments 15,699 sh (+30.62%)
Jim Simons 278,112 sh (+23.22%)
Ken Fisher 33,954 sh (+9.30%)
John Paulson 6,844,800 sh (+0.58%)
First Eagle Investment 4,830 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Leon Cooperman Sold Out
» More
Q1 2016

SHPG Guru Trades in Q1 2016

Lee Ainslie 1,630 sh (New)
David Dreman 154 sh (New)
First Eagle Investment 47,032 sh (+873.75%)
Steven Cohen 197,200 sh (+70.29%)
Ken Fisher 39,657 sh (+16.80%)
Jim Simons 313,212 sh (+12.62%)
John Paulson 7,071,050 sh (+3.31%)
Paul Tudor Jones 80,000 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
John Paulson 58,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Paul Singer Sold Out
Andreas Halvorsen 130,870 sh (-4.61%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:BXLT, NAS:REGN, OTCPK:CSLLY, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:BIIB, NAS:INCY, OTCPK:UCBJF, OTCPK:NVZMY, NAS:BMRN, NAS:GRFS, OTCPK:GMXAY, NAS:MDVN, NAS:JAZZ, NAS:ALKS, NAS:DYAX, NAS:SGEN, NAS:OPK, OTCPK:SBMFF » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions. The Company offers products including VYVANSE a pro-drug stimulant for the treatment of ADHD a chronic neurobehavioral disorder; ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing; INTUNIV an alpha-2A receptor agonist indicated for the treatment of ADHD; LIALDA for the induction of remission in patients with mild to moderately active UC and for the maintenance of remission of Ulcerative Colitis (UC); PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract; REPLAGAL is marketed for the treatment of Fabry disease outside of the U.S. Fabry disease is a rare, inherited genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats; ELAPRASE a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II); VPRIV a treatment for Type 1 Gaucher disease; FIRAZYR a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE; CINRYZE a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor (C1-INH) deficiency; GATTEX/REVESTIVE for injection is the first prescription medicine for the long-term treatment of adults with SBS who are dependent on parenteral support; NATPARA (parathyroid hormone) for injection is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with HPT; FOSRENOL a phosphate binder that is indicated for use in patients with end-stage renal disease (stage 5) receiving dialysis and, is also indicated in the EU for the treatment of adult patients with Chronic kidney disease. The Company also offers other products including KALBITOR a plasma kallikrein (pKal) inhibitor for the treatment of acute attacks of HAE in patients 12 years of age and older. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the United States, the EU and other territories.

Ratios

vs
industry
vs
history
P/E(ttm) 28.58
SHPG's P/E(ttm) is ranked higher than
54% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. SHPG: 28.58 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s P/E(ttm) Range Over the Past 10 Years
Min: 12.37  Med: 25.73 Max: 74.35
Current: 28.58
12.37
74.35
Forward P/E 13.48
SHPG's Forward P/E is ranked higher than
69% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. SHPG: 13.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.99
SHPG's PE(NRI) is ranked higher than
54% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. SHPG: 27.99 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s PE(NRI) Range Over the Past 10 Years
Min: 12.85  Med: 23.71 Max: 106.93
Current: 27.99
12.85
106.93
Price/Owner Earnings (ttm) 27.28
SHPG's Price/Owner Earnings (ttm) is ranked higher than
57% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 32.52 vs. SHPG: 27.28 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.38  Med: 23.77 Max: 70.61
Current: 27.28
11.38
70.61
P/B 3.47
SHPG's P/B is ranked higher than
50% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. SHPG: 3.47 )
Ranked among companies with meaningful P/B only.
SHPG' s P/B Range Over the Past 10 Years
Min: 3.02  Med: 5.50 Max: 14.15
Current: 3.47
3.02
14.15
P/S 5.68
SHPG's P/S is ranked higher than
67% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. SHPG: 5.68 )
Ranked among companies with meaningful P/S only.
SHPG' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.58 Max: 9.23
Current: 5.68
2.25
9.23
POCF 17.44
SHPG's POCF is ranked higher than
60% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. SHPG: 17.44 )
Ranked among companies with meaningful POCF only.
SHPG' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 16.86 Max: 26.94
Current: 17.44
7.66
26.94
EV-to-EBIT 29.81
SHPG's EV-to-EBIT is ranked lower than
61% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. SHPG: 29.81 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.50 Max: 42.6
Current: 29.81
-16.1
42.6
EV-to-EBITDA 20.47
SHPG's EV-to-EBITDA is ranked lower than
52% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. SHPG: 20.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: 13.30 Max: 28.6
Current: 20.47
-21.3
28.6
PEG 1.25
SHPG's PEG is ranked higher than
68% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. SHPG: 1.25 )
Ranked among companies with meaningful PEG only.
SHPG' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.05 Max: 1.81
Current: 1.25
0.47
1.81
Shiller P/E 49.16
SHPG's Shiller P/E is ranked higher than
55% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.02 vs. SHPG: 49.16 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 108.36 Max: 469
Current: 49.16
42.92
469
Current Ratio 0.55
SHPG's Current Ratio is ranked lower than
93% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SHPG: 0.55 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.76 Max: 7.43
Current: 0.55
0.52
7.43
Quick Ratio 0.40
SHPG's Quick Ratio is ranked lower than
93% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SHPG: 0.40 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.51 Max: 7.07
Current: 0.4
0.4
7.07
Days Inventory 232.32
SHPG's Days Inventory is ranked lower than
77% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. SHPG: 232.32 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 184.44 Max: 244.29
Current: 232.32
126.5
244.29
Days Sales Outstanding 76.01
SHPG's Days Sales Outstanding is ranked lower than
59% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. SHPG: 76.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 67.24 Max: 72.82
Current: 76.01
47.71
72.82
Days Payable 124.33
SHPG's Days Payable is ranked higher than
72% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. SHPG: 124.33 )
Ranked among companies with meaningful Days Payable only.
SHPG' s Days Payable Range Over the Past 10 Years
Min: 80.31  Med: 110.24 Max: 161.12
Current: 124.33
80.31
161.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
SHPG's Dividend Yield is ranked lower than
81% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. SHPG: 0.46 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.42 Max: 0.7
Current: 0.46
0.23
0.7
Dividend Payout 0.12
SHPG's Dividend Payout is ranked higher than
90% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. SHPG: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.26 Max: 1.27
Current: 0.12
0.04
1.27
Dividend Growth (3y) 16.70
SHPG's Dividend Growth (3y) is ranked higher than
72% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 8.70 vs. SHPG: 16.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPG' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.50 Max: 57.9
Current: 16.7
0
57.9
Forward Dividend Yield 0.78
SHPG's Forward Dividend Yield is ranked lower than
70% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. SHPG: 0.78 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.02
SHPG's Yield on cost (5-Year) is ranked lower than
63% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. SHPG: 1.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.5  Med: 0.91 Max: 1.52
Current: 1.02
0.5
1.52
3-Year Average Share Buyback Ratio -2.20
SHPG's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.40 vs. SHPG: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.10 Max: 0.4
Current: -2.2
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.13
SHPG's Price/Projected FCF is ranked higher than
68% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. SHPG: 2.13 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.81 Max: 3.04
Current: 2.13
1.15
3.04
Price/Median PS Value 1.24
SHPG's Price/Median PS Value is ranked lower than
68% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. SHPG: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 0.95 Max: 2.76
Current: 1.24
0.53
2.76
Price/Peter Lynch Fair Value 1.14
SHPG's Price/Peter Lynch Fair Value is ranked higher than
71% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. SHPG: 1.14 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 2.92
Current: 1.14
0.54
2.92
Earnings Yield (Greenblatt) (%) 3.29
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. SHPG: 3.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.50 Max: 8.4
Current: 3.29
2.3
8.4
Forward Rate of Return (Yacktman) (%) 26.38
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.46 vs. SHPG: 26.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.40 Max: 29.6
Current: 26.38
1.5
29.6

More Statistics

Revenue (TTM) (Mil) $6,638
EPS (TTM) $ 6.65
Beta1.63
Short Percentage of Float1.37%
52-Week Range $147.60 - 270.63
Shares Outstanding (Mil)197.38

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 8,861 11,470 8,781
EPS ($) 14.47 16.78 17.17
EPS w/o NRI ($) 14.47 16.78 17.17
EPS Growth Rate
(3Y to 5Y Estimate)
12.76%
» More Articles for NAS:SHPG

Headlines

Articles On GuruFocus.com
Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 

More From Other Websites
Shire says ADHD drug meets main goal of study Jun 29 2016
Shire's stock surges after ADHD drug trial meets key endpoints Jun 29 2016
7:01 am Shire announces positive topline results of SHP465 efficacy and safety study in adults with... Jun 29 2016
Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD Jun 29 2016
Will Lifitegrast Be Approved in 2016? Jun 28 2016
What Is Shire’s Outlook for 2016? Jun 22 2016
Will Lifitegrast Be Approved in 2016? Jun 21 2016
'Mad Money' Lightning Round: I'm Sticking With Southwest Airlines Jun 16 2016
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug Jun 15 2016
[$$] Allergan, Teva Set to See Catalysts Jun 15 2016
SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 15 2016
Why Best Buy, Celgene, and Three Other Stocks Are Making Headlines Today Jun 15 2016
Director/PDMR Shareholding Jun 15 2016
Shire and Kamada announce FDA approval ... Jun 15 2016
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the... Jun 15 2016
Shire Gets Breakthrough Status for Rare Disease Candidates Jun 14 2016
SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 14 2016
Smith & Wesson Giving Back Yesterday’s Gains, Plus 4 Other Sinking Stocks Jun 14 2016
Additional Listing Jun 14 2016
Pfizer and Shire Move on IBD License Agreement Jun 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)